212Pb-PRRT

**212Pb-PRRT** is an early discovery-stage **lead-212 labeled peptide receptor radionuclide therapy** program from **Orano Med**, including partnered efforts with **48Hour Discovery** and **Biosynth**. It is a **targeted alpha therapy radiopharmaceutical** in which an undisclosed tumor-targeting peptide vector is linked to the alpha-emitting isotope **lead-212**, with the goal of delivering cytotoxic alpha radiation selectively to cancer cells expressing the relevant receptor. Publicly available information indicates that the specific peptide sequence, exact molecular target or targets, and precise tumor indications have **not been disclosed**; the program is described broadly as being intended for **various cancers** and remains in **discovery**.

Other names

212Pb PRRT²¹²Pb-PRRT²¹²Pb PRRT212Pb PRRT Program 1212Pb PRRT Program 2